Kakao Healthcare said on the 12th that it signed an exclusive domestic supply contract with Dexcom, a global glucose biosensing corporations.
Under the agreement, Kakao Healthcare will be responsible for domestic distribution and market operations for Dexcom's continuous glucose monitoring (CGM) portfolio and for expanding its user base. In particular, it plans to improve accessibility and increase the number of domestic users, focusing on the "Dexcom G7" continuous glucose monitor.
The two companies will also build a new digital-based health management model by combining Kakao Healthcare's digital platform with Dexcom's glucose biosensing technology. Going beyond simple glucose monitoring, they plan to advance it into a hyper-personalized health management service by linking lifestyle data—exercise, diet, sleep, and stress—with glucose data.
Jennifer Cho, Dexcom's head of APAC business, said, "This collaboration shows Dexcom's commitment to actively integrating artificial intelligence (AI)-based digital features into future product lineups," adding, "Kakao Healthcare is the optimal partner to bring this innovation to market."
Hwang Hee, CEO of Kakao Healthcare, said, "After a year and a half of collaboration with Dexcom, it is meaningful that we have been able to establish a closer business relationship," and added, "We also expect to expand services for hospitals based on synergies with CHA Bio Group's Cha Cares and Cha AI Healthcare."